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Available online xxxxBackground: Status epilepticus (SE) is a life-threatening neurologic emergency, which requires prompt medical
treatment. Little is known of the long-term survival of SE. The aim of this study was to investigate which factors
influence 90 days and 1-year mortality after SE.
Materials and methods: This retrospective study includes all consecutive adult (N16 years) patients (N = 70)
diagnosedwith generalized convulsive SE (GCSE) in Helsinki University Central Hospital (HUCH) emergency de-
partment (ED) over 2 years. We defined specific factors including patient demographics, GCSE characteristics,
treatment, complications, delays in treatment, and outcome at hospital discharge and determined their relation
to 90 days and 1-year mortality after GCSE by using logistic regression models. Survival analyses at 1 year after
GCSE were performed with Cox proportional hazards regression analysis.
Results: In-hospital mortality was 7.1%. Mortality rate was 14.3% at 90 days and 24.3% at 1 year after GCSE. In the
univariate logistic regression analysis, Status Epilepticus Severity Score N 4 (STESS) (ODDS = 7.30, p = 0.012),
worse-than-baseline condition at hospital discharge (ODDS = 3.5, p = 0.006), long delays in attaining seizure
freedom (ODDS = 2.2, p = 0.041), and consciousness (ODDS = 3.4, p = 0.014) were risk factors for mortality
at 90 days whereas epilepsy (ODDS = 0.2, p = 0.014) and Glasgow Outcome Scale (GOS) N3 at hospital dis-
charge (ODDS = 0.05, p = 0.006) were protective factors. Risk factors for mortality at 1 year were STESS N4
(ODDS = 5.1, p = 0.028), use of vasopressors (ODDS = 8.2, p = 0.049), and worse-than-baseline condition at
discharge (ODDS = 7.8, p = 0.010) while GOS N3 (ODDS = 0.2, p = 0.005) was protective.
The univariate survival analysis at 1 year confirmed the significant findings regarding parameters STESS N4
(Hazard ratio (HR)= 4.1, p=0.009), worse-than-baseline condition (HR= 6.2, p=0.015), GOS N3 (HR=
0.2, p=0.004) at hospital discharge and epilepsy (HR= 0.4, p=0.044). Additionally, diagnostic delay over
6 h (HR= 3.8, p=0.022) and Complication Burden Index (CBI) as an ordinal variable (0–2, 3–6, N6) (HR=
2.7, p = 0.027) were predictive for mortality.
In the multivariate survival analysis, STESS N 4 (HR = 5.1, p = 0.007), CBI (HR = 3.2, p = 0.025, ordinal
variable), diagnostic delay over 6 h (HR = 7.2, p = 0.003), and worse-than-baseline condition at hospital
discharge (HR = 5.8, p = 0.027) were all independent risk factors for mortality at 1 year.
Conclusions: Severe form of SE, delayed recognition of GCSE, high number of complications during treat-
ment period, and poor condition at hospital discharge are all independent predictors of long-term mortal-
ity. Most of these factors are also associated with mortality at 90 days, though at that point, delays in
treatment seem to have a greater impact on prognosis than at 1 year.
This article is part of the Special Issue “Proceedings of the 7th London-Innsbruck ColloquiumonStatus Epilepticus
and Acute Seizures
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Status epilepticus (SE) is a life-threatening medical emergency,
which requires prompt medical treatment and is associated with sub-
stantial morbidity and mortality. The incidence of SE ranges from 10
to 20 per 100,000 andmortality between 1.9 and 40% in published stud-
ies [1]. Factors related to poor short-term outcome include old age,
symptomatic etiology, refractoriness, comorbidities, poor premorbidet al., Predictors of mortality at one year after generalized convulsive
19.07.012
Table 1
Patient demographics, GCSE characteristics, parameters for treatment, complications and




Gender Male 35 50
Female 35 50
Age under 65 Yes 51 72.9
No 19 27.1
Epilepsy Yes 46 65.7
No 23 32.9
Unknown 1 1.4





Premorbid GOS 1–3 5 7
GCSE characteristics




Prestatus period Yes 14 20.0
No 56 80.0
SE onset Continuous 45 64.3
Intermittent 25 35.7
Refractoriness Non-SRSE 38 54.3
SRSE 32 45.7
Treatment and complications
Anesthetic treatment No anesthesia 8 11.4
Only propofol 56 80
Multiple anesthetics 6 8.6
Burst-suppression obtained Yes 30 42.9
No 40 57.1
Complication burden index (CBI) 0–3 38 54.3
N3 32 45.7
Use of vasopressors Yes 51 72.9
No 19 27.1
Mechanical ventilation Yes 62 88.6
No 8 11.4
Infections Yes 61 87.1
No 9 12.9
Outcome
GOS at discharge ≤3 28 40
N3 42 60
Condition at discharge Worse-than-baseline 41 58.6
Baseline 29 41.4
In-hospital mortality Yes 5 7.1
No 65 92.9
90 d mortality Yes 10 14.3
No 60 85.7
1 year mortality Yes 17 24.3
No 53 75.7
2 K.M. Tuppurainen et al. / Epilepsy & Behavior xxx (xxxx) xxxcondition, long duration of SE, and complications and delays in the
treatment [2–12]. Most of these outcome predictors have been incorpo-
rated in outcome scores Status Epilepticus Severity Score (STESS) [13],
modified STESS (mSTESS) [8], and epidemiology-based mortality score
in status epilepticus (EMSE) [14]. These scores have been developed
for the in-hospital mortality prediction of SE. The predictive value of
these scores has been externally validated, although the optimal predic-
tive cutoff for STESS varies between the studies [15–17].
Up to date, the knowledge of long-term survival of SE is considerably
more limited than that of short-term mortality. A recent review of alto-
gether 37 studies reported a substantial long-term mortality with a
wide range [18]. Ninety days mortality ranged from 14% to 50% [18–20],
and mortality after at least 1-year of follow-up ranged from 23% to 57%
[6,18,21]. There are only a few studies regarding factors affecting long-
term mortality after SE, and the results are somewhat inconsistent. In
most studies, symptomatic or potentially fatal etiology, older age, long du-
ration of SE, refractoriness, and dependence in active daily living (ADL)
functions have been shown to predict poor long-term outcome after SE
[6,18,22,23], however, there are also opposite results [24]. The predictive
value of STESS for long-term mortality remains unconfirmed, since in
some studies, it does not validate as a long-term predictor [18,24,25], al-
though there are also promising results [22,26,27]. On the other hand,
EMSE score has been associatedwith poor long-termoutcome in one pro-
spective study [27]. Still, the association of delays and complications in the
treatment with long-term mortality remains undefined.
The aim of this study was to investigate which factors affect mortal-
ity of generalized convulsive SE (GCSE) after 90 days and 1 year.
2. Materials and methods
2.1. Study design and setting
This is a retrospective cohort study performed in Helsinki University
Central Hospital (HUCH). This study conforms to the Finnish legislation
concerning medical research, and the permission was granted by the
HUCH Department of Neurology.
Helsinki University Central Hospital is a tertiary hospital serving a
population of 1.4 million, and the emergency department (ED) offers
24h neurological emergency service to the entire hospital district. In ad-
dition to HUCH, the hospital district is served by seven regional hospi-
tals with EDs run by internists and several healthcare centers. The
local emergency medical service (EMS) is instructed to transport any
patient independent in daily living with GCSE primarily to HUCH ED.
At the time of the study period, EMS had the possibility to administer
first- and third-stage treatments of SE, and second-stage treatment
was administered in the ED.
2.2. Definition of GCSE
At the time of material collection, established SEwas defined as con-
tinuous seizures lasting over 30min, several recurrent seizures without
return of consciousness or occurrence of more than four seizures within
any 1 h irrespective of return of consciousness in between. Patients hav-
ing a convulsive seizure at any point of the SE periodwere considered as
having convulsive SE (CSE). Patients with impaired consciousness, ei-
ther primarily or secondarily, were considered as having generalized
SE (GSE).
2.3. Selection of participants
This study includes 70 consecutive adult patients (≥16 years) diag-
nosed with GCSE and treated in the HUCH ED between January 2002
and December 2003.
The patients were identified in the HUCH electronic patient database
by the International Classification of Diseases Tenth Revision (ICD-10)
code G41 (SE), yielding a total of 87 patients. Patients not meeting thePlease cite this article as: K.M. Tuppurainen, J.G. Ritvanen, H. Mustonen,
status epilepticus, Epilepsy & Behavior, https://doi.org/10.1016/j.yebeh.20criteria of GCSE were excluded. A total of 70 patients with GCSE were el-
igible for the study.
2.4. Data collection
Clinical data were collected by a trained medical doctor from the
original medical records and recorded into an electronic database. Pa-
tient identification information was removed before further analyses.
Patient demographics, GCSE characteristics, parameters for treat-
ment and complications, and measures of outcome were collected for
all cases. These parameters are presented in Table 1. In addition, we
identified nine specific delay parameters in the management of GCSE,
which are presented in Table 2. For determining the accuracy and reli-
ability of the collected time parameters, we calculated the weighted ac-
curacy score (LWAS) and the data availability (DA), using the method
developed for evaluation of retrospective delay materials [28].et al., Predictors of mortality at one year after generalized convulsive
19.07.012
Table 2
Delay parameters and the delays in the treatment.
Variable N % Time Min Max DA LWAS
All cases 70 100 Median %
Delays in the treatment
Onset-to-initial-treatment 67 95.7 30 min 0 min 8 h 5 min 97.0 1.8
Onset-to-diagnosis 70 100 1 h 48 min 6 min 60 h 6 min 97.1 1.5
Onset-to-second-stage-medication 67 95.7 2 h 40 min 30 min 61 h 54 min 98.5 1.6
Onset-to-tertiary-hospital (HUCH) 70 100 2 h 25 min 37 min 277 h 40 min 98.6 1.5
Onset-to-burst-suppression 30 42.9 14 h 42 min 5 h 5 min 137 h 50 min 100 1.5
Onset-to-seizure-freedom 70 100 5 h 15 min 26 min 533 h 15 min 98.6 1.6
Onset-to-consciousness 61 87.1 42 h 45 min 2 h 40 min 444 h 40 min 96.7 1.4
Length-of-the-anesthesia-treatment 62 88.5 38 h 3 h 35 min 238 h 52 min 98.4 1.1
Length-of-the-ICU-treatment 63 90 58 h 40 min 7 h 45 min 520 h 25 min 100 1.1
3K.M. Tuppurainen et al. / Epilepsy & Behavior xxx (xxxx) xxxOutcome at hospital discharge was collected from medical records.
Long-term mortality up to 1 year was gathered from the causes of
death — register maintained by Official Statistics of Finland.
Missing events, e.g., no burst-suppression (BS), events happening
during prestatus period, or unknown data were excluded from the
final analysis. The missing data information is presented in Online
Table 1.
2.5. Definitions of measures
Age of 65 years was selected as the classification basis for age as a
grouping variable. Only patients with previously diagnosed epilepsy
were considered as having epilepsy, previous epilepsy serving as
surrogate for etiology of GCSE. Comorbidity was scored according
to Charlson Comorbidity Index (CCI) [29]. Underlying etiologies for
GCSE were not scored in CCI. Status Epilepticus Severity Score was
calculated for all patients [13]. Seizures occurring up to 48 h prior
to GCSE onset were referred to as prestatus period seizures. Seizures
lasting at least 30min clinically were defined as continuous. All other
types of seizures were considered as intermittent. Patients' seizures
failing to respond to first- or second-stage treatment were consid-
ered as refractory SE (RSE). Status epilepticus continuing or recur-
ring 24 h or more after the onset of anesthesia was considered as
superrefractory SE (SRSE). The anesthetic treatment was grouped
as no anesthesia, only propofol or multiple anesthetics. For the eval-
uation of complications during treatment period, the Complication
Burden Index (CBI) with a cutoff point of N3 and as a continuous var-
iable were used [9]. Functional outcome at hospital discharge was
considered good when condition returned to baseline and Glasgow
Outcome Scale (GOS) was N3.
The onset of GCSE was defined as the beginning of the first sei-
zure, fulfilling the criteria for established GCSE. Initial treatment
was defined as the first given antiepileptic drug (AED), which was
not necessarily the first-stage medication. The second-stage medica-
tion was defined as first given second-stage medication, mainly in-
travenous (i.v.) phosphenytoin. Diagnosis of GCSE was made by the
EMS or ED physician on clinical grounds or with the aid of Electroen-
cephalogram (EEG) recording. Tertiary hospital referred to HUCH ED
at all times. The cessation of GCSE was defined with three separate
parameters for the treatment response [28]: BS, clinical seizure free-
dom, and return of consciousness. Burst-suppression refers to the
beginning of the first BS sequence during this SE. Clinical seizure
freedom refers to the end of the last clinical convulsion, and return
of consciousness refers to the time point, when the patient no longer
presented with altered mental status. The length of treatment
(anesthesia/Intensive Care Unit (ICU)) was calculated by adding up
the total length of all individual anesthesia- / ICU-periods during
the GCSE.
Long-term outcome of the patients was defined as mortality at
90 days, 1 year, or during the 1-year follow-up period.Please cite this article as: K.M. Tuppurainen, J.G. Ritvanen, H. Mustonen,
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Results are given as number of cases and percentage or median and
interquartile range (IQR).
Ninety days and 1-year mortality were analyzed with univariate lo-
gistic regression analyses. Survival analyses at 1 year were performed
with the Cox proportional hazards regression analysis and the
Kaplan–Meier method with the log rank test.
Parameters for multivariate analysis at 1 year were selected based
on univariate analyses and clinical relevance. Significant parameters
correlating statistically or clinicallywere excluded from themultivariate
models. Parameters selected for multivariate Cox proportional hazards
analysis were STESS N4, CBI as an ordinal variable (0–2, 3–6, N6),
worse-than-baseline condition at hospital discharge, and diagnostic
delay with cutoff at 6 h.
p values b0.05 are considered significant, and two tailed tests were
used. Statistical analyses were performed with the SPSS software (ver-
sion 24.0, IBM Corp., NY, USA).
3. Results
In-hospitalmortalitywas 7.1% in this study.Mortality ratewas 14.3%
at 90 days and 24.3% at 1 year after GCSE.
In the univariate logistic regression analysis, STESS N4 (ODDS =
7.30, p = 0.012), worse-than-baseline condition at hospital discharge
(ODDS = 3.5, p = 0.006), long delays in attaining seizure freedom
(ODDS = 2.2, p = 0.041), and long delays in gaining consciousness
(ODDS= 3.4, p=0.014) were risk factors for mortality at 90 days. Pre-
viously diagnosed epilepsy (ODDS = 0.2, p = 0.014) and good condi-
tion at hospital discharge evaluated with GOS N3 (ODDS = 0.05, p =
0.006) were protective factors regarding mortality at 90 days.
Status Epilepticus Severity Score N4 (ODDS= 5.1, p=0.028), use of
vasopressors (ODDS=8.2, p=0.049), andworse-than-baseline condi-
tion at discharge (ODDS= 7.8, p=0.010) were risk factors for mortal-
ity at 1 year, whereas GOS N3 at hospital discharge (ODDS = 0.2, p =
0.005) was protective.
Complication Burden Index was analyzed with a cutoff point of 3,
which proved insignificant for predicting mortality in this study. How-
ever, CBI as a continuous variable had slightly better but insignificant re-
sults in predicting both 90 days (p= 0.093) and 1-year mortality (p=
0.066) after GCSE. Delay parameters just not reaching statistical signifi-
cance in predicting mortality at 90 days were onset-to-diagnosis-time
(p = 0.054), onset-to-tertiary-hospital time (p = 0.05), onset-to-BS
time (p = 0.085), and length-of-ICU-treatment (p = 0.063). At 1 year,
length-of-ICU-treatment remained slightly below significant associa-
tion with mortality (p = 0.057).
The results of the comprehensive univariate analysis are presented
in Table 3.
The univariate survival analysis with Cox proportional hazards regres-
sion analysis at 1 year confirmed the significant findings regardinget al., Predictors of mortality at one year after generalized convulsive
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Table 3
The results of the comprehensive univariate analysis.
Variable All cases 90 days mortality 1 year mortality
Dead Alive 95%
CI




N (%) N (%) N (%) ODDS Min Max p N (%) N (%) ODDS Min Max p
Demographics 70 (100) 10 (14) 60 (86) 17 (24) 53 (76)
Gender Male 35 (50) 6 (60) 29 (48) 1.60 0.40 6.30 0.497 10 (59) 25 (47) 1.60 0.50 4.80 0.405
Age N65 19 (27) 4 (40) 15 (25) 2.00 0.50 8.10 0.330 6 (35) 13 (25) 1.70 0.50 5.40 0.388
Epilepsy Yes 46 (66) 3 (30) 43 (72) 0.20 0.00 0.70 0.014 8 (47) 38 (72) 0.30 0.10 1.00 0.053*
CCI N2 18 (26) 1 (10) 17 (28) 0.28 0.03 2.39 0.245 3 (18) 15 (28) 0.54 0.14 2.16 0.387
GCSE characteristics
STESS N2 35 (50) 7 (70) 28 (47) 2.70 0.60 11.30 0.183 10 (59) 25 (47) 1.60 0.50 4.80 0.405
STESS N3 19 (27) 4 (40) 15 (25) 2.00 0.50 8.10 0.330 6 (35) 13 (25) 1.70 0.50 5.40 0.388
STESS N4 9 (13) 4 (40) 5 (8) 7.30 1.50 35.00 0.012 5 (29) 4 (8) 5.10 1.20 21.90 0.028
Prestatus period Yes 14 (20) 1 (10) 13 (22) 0.40 0.00 3.50 0.407 2 (12) 12 (23) 0.50 0.10 2.30 0.338
SE onset Intermittent 25 (36) 4 (40) 21 (35) 1.20 0.30 4.90 0.760 5 (29) 20 (38) 0.70 0.20 2.20 0.534
Refractoriness SRSE 32 (46) 6 (60) 26 (43) 2.00 0.50 7.70 0.333 9 (53) 23 (42) 1.50 0.50 4.40 0.493
Treatment and complications
Anesthetic
treatment Only propofol 56 (80) 8 (80) 48 (80) 1.20 0.10 10.80 0.892 14 (82) 42 (79) 2.30 0.30 20.70 0.446
Burst-suppression Yes 30 (43) 7 (70) 23 (38) 3.80 0.90 16.00 0.074* 9 (53) 21 (40) 1.70 0.60 5.10 0.227
Use of
vasopressors Yes 51 (73) 9 (90) 42 (70) 3.90 0.50 32.70 0.216 16 (94) 35 (66) 8.20 1.00 67.10 0.049
Mechanical
ventilation Yes 62 (89) 9 (90) 53 (88) 1.20 0.10 10.80 0.878 16 (94) 46 (87) 2.40 0.30 21.30 0.422
CBI N3 32 (46) 7 (70) 25 (42) 3.27 0.77 13.88 0.190 9 (53) 23 (43) 1.47 0.49 4.39 0.493
CBI Continuous variable 70 (100) 10 (100) 60 (100) 1.30 0.96 1.78 0.093* 17 (100) 53 (100) 1.29 0.98 1.70 0.066*
Infections Yes 61 (87) 10 (100) 51 (85) 0.999 16 (94) 45 (85) 2.80 0.33 24.56 0.342
Outcome at hospital discharge
GOS N3 42 (60) 1 (10) 41 (68) 0.050 0.006 0.436 0.006 5 (29) 37 (70) 0.18 0.05 0.60 0.005










Onset-to-initial-treatment 0.5 (0.8) 0.2 (0.9) 0.5 (0.7) 0.6 0.2 1.9 0.265 0.3 (0.6) 0.5 (0.8) 0.7 0.3 1.5 0.318
Onset-to-diagnosis 1.8 (2.8) 3 (10.8) 1.7 (2.6) 4.3 0.8 156.6 0.054* 2 (5) 1.6 (2.6) 1.9 0.5 12.4 0.26
Onset-to-second-stage-treatment 2.7 (3.4) 4.8 (6.2) 2.6 (2.2) 3.1 0.3 116.1 0.24 3.4 (4.6) 2.6 (2.2) 1.3 0.2 9 0.726
Onset-to-tertiary-hospital 2.4 (2.8) 3.9 (25) 2.3 (2.6) 3.1 0.4 38.5 0.057* 2.4 (3.9) 2.4 (2.6) 1.6 0.3 6.8 0.412
Onset-to-burst-suppression 14.7 (19) 28.5 (32.8)
12.5
(18.3)
9.6 0.4 24,612.3 0.085* 22 (28.7) 14 (19.3) 2.4 0.1 609 0.488








3.4 1.6 12.2 0.014
57.9
(68.8)
38 (53.1) 2.2 0.6 12.5 0.226
Length-of-the-anesthesia-treatment 38 (51.2) 39.5 (68.5) 36 (50.7) 3.6 0.9 23.6 0.223
36.9
(66.2)












3.1 1 13.6 0.057*
Time (h) Median time in hours. IQR Interquartile range. **min-max. Only 3 patients. Statistical significance (p b 0.05) is expressed in bold. Statistical trend (p b 0.1) is expressed with *.
4 K.M. Tuppurainen et al. / Epilepsy & Behavior xxx (xxxx) xxxparameters STESS N4 (HR=4.1, 95%Confidence Interval (CI) 1.43–11.67,
p=0.009), worse-than-baseline condition (HR= 6.2, 95%CI 1.42–27.21,
p=0.015), GOS N3 at hospital discharge (HR=0.2, 95%CI 0.08–0.62, p=
0.004), and epilepsy (HR=0.4, 95%CI 0.14–0.98, p=0.044). Vasopressor
use (HR=6.92, 95%CI 0.92–52.2, p=0.061) and CBI as a continuous var-
iable (HR = 1.2, 95%CI 0.99–1.48, p = 0.067) remained below the
significance.
Continuous variables i.e., delays in treatment and CBIwere tested for
cutoffs with Receiver operating characteristic curve (ROC-curve) calcu-
lations. In survival analysis, diagnostic delay over 6 h (HR = 3.8, 95%CI
1.21–11.7, p = 0.022) and CBI as an ordinal variable (0–2, 3–6, N6)
(HR = 2.7, 95%CI 1.12–6.6, p = 0.027) were found to be predictive for
mortality, as also seen in Kaplan–Meier curves (Figs. 1 and 2). Onset-
to-burst-suppression time with a cutoff of 17.5 h (HR = 3.5, 95%CI
0.88–14.2, p = 0.075) was not quite statistically significant.
Results of the multivariate survival analysis are presented in
Table 4. Status Epilepticus Severity Score N4 (HR = 5.1, p = 0.007),
CBI (HR = 3.2, p = 0.025, ordinal variable), diagnostic delay over
6 h (HR = 7.2, p = 0.003), and worse-than-baseline condition atPlease cite this article as: K.M. Tuppurainen, J.G. Ritvanen, H. Mustonen,
status epilepticus, Epilepsy & Behavior, https://doi.org/10.1016/j.yebeh.20hospital discharge (HR = 5.8, p = 0.027) were all independent risk
factors for mortality at 1 year.
4. Discussion
This study brings notable additional information to the field of long-
term outcome after GCSE by being the first study also investigating the
effect of the delays and complications in the treatment on long-term
mortality after GCSE.
Although delays are significant predictors of short-term outcome,
the effect seems to reduce as time increases after GCSE. Consequently,
at 90 days, several delays still have some effect on mortality while at
one year, the effect on outcome has nearly been lost. However, diagnos-
tic delay over 6 h remains a strong predictor for mortality. Additionally,
poor functional outcome at hospital discharge, high number of compli-
cations during treatment period, and severity of GCSE graded with
STESS proved to be independently associated with long-termmortality.
All retrospective studies bear a risk of reporting bias. To cover this bias,
we used previously developed scores Lwas and DA to determine theet al., Predictors of mortality at one year after generalized convulsive
19.07.012
Fig. 1. Kaplan–Meier curve showing the significant difference of effect of the diagnostic delay (b6 h vs. ≥6 h) on mortality during the 1-year follow-up period after GCSE (p = 0.014).
Fig. 2. Kaplan–Meier curve showing the significant difference of the CBI (0–2, 3–6, N6, ordinal variable) on mortality during the 1-year follow-up period after GCSE (p = 0.029).
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Table 4
The results of the multivariate survival analysis at 1 year after GCSE.
Variable HR 95%CI 95% CI p
Min Max
STESS N4 5.13 1.57 16.77 0.007
CBI 0–2/3–6/N6 3.19 1.16 8.82 0.025
Onset-to-diagnosis N6 h 7.19 1.92 26.99 0.003
Condition at discharge Worse-than-baseline 5.78 1.23 27.24 0.027
6 K.M. Tuppurainen et al. / Epilepsy & Behavior xxx (xxxx) xxxaccuracy and reliability of the collected time parameters. The Finnish EMS
is very punctual in its markings guaranteeing a high level of accuracy,
which is highlighted in a good Lwas and DA throughout the study.
Thematerial in this study is relatively old, and at the time of data col-
lection, the definition of SE was a seizure lasting for at least 30 min, in-
stead of the current definition of 5 min. However, the treatment
protocols have not markedly changed during the past 15 years, and
therefore, the material is comparable with studies with newer data.
Nowadays, EEG recording in the acute phase is readily available in the
ED in Helsinki whereas at the time of material collection, acutely regis-
tered EEG data were nearly lacking. For this reason, the calculation of
EMSE score was not possible in this material.
The sample size is relatively small, whichmay be seen as the biggest
limitation of our study. Nevertheless, it is fairly comparable with the
sample sizes in previous studies. According to the patient distribution
protocol, patients not independent in ADL functions are treated in re-
gional hospitals and not in HUCH. Therefore, they are not included in
this material. The large proportion of patients with RSE and SRSE in
this material highlights the tertiary hospital status of HUCH, where the
most difficult cases of GCSE are treated in Southern Finland. These fac-
tors result in patient selection bias in our study population. However,
it may enable us to diminish the effect of overall frailty of patients on
long-term prognosis and focus more on the factors related solely to
SE. These abovementioned limitations may warrant some precaution
in interpreting the results of this study.
4.1. Mortality
Mortality increased from in-hospital mortality up to one year, when
about one-fourth of the patients had died. While this seems quite high,
it is, in fact, in the lower range of long-termmortality reported in previ-
ous studies [6,18–21]. This may partly reflect the overall good
premorbid condition in our study population due to patient selection.
4.2. Outcome score variables
In this study, STESSwas associatedwith poor long-term prognosis of
GCSEwith a score N4. Studies regarding the prognostic value of STESS as
an indicator of long-term outcome have been published with opposing
results [18,22,24–27]. In one study, all individual components of STESS
except “history of previous seizures” seemed to be associated with
long-termmortality, but overall STESS with a cutoff of 4 was not associ-
atedwith survival after discharge [24]. The prognostic value of STESS for
long-term outcome is still unclear, but the results of this present study
are indicative of its usefulness in predicting long-term mortality,
which possibly broadens the usability of the score and could serve as a
basis for the future development of new outcome scores used for pre-
diction of long-term outcome.
A few studies have investigated the role of EMSE score in predicting
long-term outcome of SE with promising results [26,27]. In a recent
study by Møller et al., epidemiology-based mortality score in status ep-
ilepticus, etiology-age-comorbidity-EEG (EMSE-EACE)was significantly
associated with mortality after discharge, but in the same patients,
STESS ≥3 reached only borderline significance and STESS ≥4 was not
statistically significant [26]. Because of the lacking EEG recordings onPlease cite this article as: K.M. Tuppurainen, J.G. Ritvanen, H. Mustonen,
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termined in this study.
The protective value of previous epilepsy on mortality seen in this
study possibly reflects the worse prognosis of severe symptomatic
causes resulting in SE. This finding is in line with other studies, where
acute symptomatic, progressive symptomatic, and potentially fatal eti-
ologies have been seen to predict long-termmortality [18,23,27,30]. Al-
thoughKantanen et al. could not confirm the positive predictive value of
earlier epilepsy at 1 year after SE, they found that the poor outcome in
patients with preexisting epilepsy was related to remote symptomatic
etiology or to a progressive syndrome, indicating that also, patients
with epilepsy are at risk for etiologies with unfavorable outcome [24].
Older age has been associated with worse long-term outcome [6,18,
30], but individual patients up to the age of 79 years have been reported
to recover functionally after RSE [24]. In our study, we could not confirm
the significance of age as an individual parameter predicting long-term
mortality. This findingmay at least partly be explained by the patient dis-
tribution protocol in HUCH area directing patients dependent in ADL
functions to regional hospitals. Since dependence of aid due to illness
and frailty is more common in the elderly population, the patient selec-
tion might influence our results regarding the prognostic value of age
on mortality. The effect of the premorbid condition on the long-term
prognosis has been reported earlier [6]. Because of the patient distribution
protocol in HUCH, only a clear minority of patients in our material had a
premorbid GOS of b4, thus, the effect onmortality could not be analyzed.
4.3. Functional outcome at hospital discharge
Only one study has previously reported the significance of condition
at hospital discharge on long-term mortality, where modified Rankin
Scale (mRS) N2was the predictor [31]. In our study, the condition at dis-
charge was evaluated categorically with GOS and comparatively to
baseline condition prior SE. Poor condition in any of these measures
was a significant predictor of mortality at 1 year after GCSE. Since asso-
ciations between delays in the treatment and functional outcome at dis-
charge have been reported [11], this new finding highlights even more
the importance of how effectively patients with SE should be managed
in the early phases of the SE.
4.4. Duration of SE and delays in the treatment
Long duration of SE is a reported risk factor for long-term mortality
[18,22,23]. Definition of SE duration alternates between SE studies, since
the exact endpoint of SE is conceptually problematic and used definitions
contain variability [32,33]. We used stepwise definition for the end of
GCSE as described in Section 2.5 and found that the longer the duration
from SE onset to seizure-freedom and to return of consciousness, the
higher the mortality rate at three months after GCSE. A previous study
of this same cohort showed that delay in return of consciousness was re-
lated to poor outcome at hospital discharge and in-hospitalmortality [11].
Interestingly, predictive association of this delay with mortality found at
discharge and at 90 days was lost at 1-year follow-up.
Delays in the treatment of SE are associated with short-term out-
come among both pediatric and adult patients [11,12]. The need tomin-
imize delays and optimize every component in the treatment chain has
been shown to be an important determinant of outcome [11]. None of
the previous studies have focused on the effect of delays on long-term
mortality. Although most of the delays in treatment in our study did
not reach significance, several delays showed trend-like effect on mor-
tality at 90 days. Nonetheless, we found that if the delay in diagnosing
GCSE exceeded 6 h, it had a significant effect on long-term survival.
The same phenomenon has been reported with short-term outcome,
where diagnostic delay over 2.4 h was predictive [11]. These findings
elucidate the importance of early diagnosis of SE. Electroencephalogram
(EEG) is not available in EMS, and 24/7 EEG-recording possibilities are
lacking in most of the EDs. Therefore, the diagnosis of SE in the earlyet al., Predictors of mortality at one year after generalized convulsive
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lished ADAN scale (Abnormal speech, eye deviation, automatism, num-
ber of seizures) might bring some help for the clinical evaluation [34];
however, substantial effort should be accomplished to improve the di-
agnostic facilities.
4.5. Refractoriness and ICU treatment
Superrefractoriness in SE has been reported to be an independent
risk factor for long-term mortality in a material based on ICU-treated
SE cases [6]. This relation between superrefractoriness and long-term
mortality could not be confirmed in this study, which might be partly
explained by the different study designs.
Refractory cases mostly require ICU treatment, which might be
prolonged especially in SRSE cases. Prolonged hospital and ICU treat-
ment periods are associated with poor outcome andmortality at hospi-
tal discharge [4,10]. On the contrary, a previous study concluded that
the length of ICU treatment did not differ between patients with good
and poor long-term outcomes [24]. This finding is partially in line with
our results, where the length of ICU treatment was not an independent
predictor of long-term mortality, although a trend-like association was
found.
In earlier studies, intravenous anesthetic drug (IVAD) treatment it-
self has not been associated with short-term mortality [35] nor the
long-term mortality after SE [22]. These findings are supported by our
results. We could neither find difference between the use of propofol
only compared with the use of multiple anesthetics. Long anesthesia
time has been associated with poor short-term outcome [11,36], how-
ever, similar association was not found in predicting long-term mortal-
ity in this present study.
Treatment complications increase as the length of the SE period in-
creases [37], and complications might be one of the reasons for poor out-
come in long SE treatment episodes [4]. Intensive Care Unit (ICU) and
IVAD treatments are risk factors for infections, hypotension, need for intu-
bation and mechanical ventilation, and other systemic complications [3,
38]. Vasopressor use, infections, andmechanical ventilation have been as-
sociated with short-term outcome in previous publications [10,36,39].
Most of these factors do not increase long-term mortality [22], however,
sepsis and severity of organdysfunction (Sequential Organ FailureAssess-
ment Score (SOFA score)) are associatedwith poor long-termoutcome [6,
22]. In this study, vasopressor use was associated with mortality at one
year. Furthermore, our study showed that an increasing total number of
complications was independently associated with long-term mortality.
This finding increases the importance of high quality in intensive care
but also underlines the importance of measures taken to prevent
nonrefractory SE evolving to RSE.
5. Conclusion
Results of this study show that the severity of SE, number of treatment
complications, diagnostic delay over 6 h, and poor functional condition at
hospital discharge have significant effect on long-term prognosis of GCSE.
Thesefindings demand for aggressive treatment of SE aiming for early sei-
zure termination, shorter treatment periods, and fewer complications
during the treatment. Our study underlines the importance of rapid diag-
nostics of SE also on long-term survival, highlighting the need for EMS
personnel education, on-call EEG availability and development, and im-
plementation of SE recognition algorithms.
Interestingly, our study showed that prognostic factors for mortality
changed over the 1-year follow-up period, from 90 days to 1 year, thus,
it is presumable that the predictive factors keep on changing as time
passes by. The knowledge ofmortality and causes of death during a lon-
ger follow-up period than 1 year is limited, which claims for further
studies.
Supplementary data to this article can be found online at https://doi.
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